Type 1 diabetes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 21
• SGLT2 12
• NRF2 0
• CTLA-4 0
• STAT3 0
• AKT 0
• GIP 2
• PD-1 0
• SIRT1 0
• CD40 0
• PPAR 0
• TP53 0
• JAK 1
• JNK 0
• mTOR 0
• NLRP3 1
• TLR4 0
• AMPK 0
• DPP-4 0
• IL-6 0
• TNF 0
• IL-1 0
• IL-17 0
• MAPK 0
• PI3K 0
• VEGF 1
• CD47 0
• HMGB1 0
• PD-L1 0
• ACE2 0
• BDNF 0
• CD19 0
• CD20 1
• CD38 0
• ERK 0
• FOXP3 0
• G6PD 0
• IL-13 0
• IL-4 0
• PCSK9 0
• RANKL 0
• STING 0
• TIGIT 0
• AR 0
• B7-H3 0
• CD22 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• GPX4 0
• HDAC 0
• HER2 0
• HER3 0
• HSP90 0
• IGF1R 0
• LAG-3 0
• METTL3 0
• MYC 0
• NMDA 0
• PDGFR 0

12 of 12+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Modeling islet inflammation in early-stage type 1 diabetes: T1DstartEd (T1Dstarted)

  The Hebrew University of Jerusalem· Jerusalem, Israel· EU contribution €2,796,250· until May 2032

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  The Inreda bi-hormonal blood glucose control pump: A beacon for high-risk diabetes patients, providing fully automated in disease management (DIABEACON)

  Inreda Diabetic Bv· Goor, Netherlands· EU contribution €2,499,414· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Type 1 Diabetes Simulator with Adjunctive therapies - GLP1 (T1SIA)

  Universitat Politecnica de Valencia· Valencia, Spain· EU contribution €243,097· until Jan 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  From harassing to harnessing beta-cells in type 1 diabetes (Beta-STEALTH)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €2,500,000· until Oct 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Uncovering Protective Mechanisms in Pancreatic β-Cells to Enhance Their Survival in Type 1 Diabetes (Beta_cell_protection)

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €200,400· until Jul 2027

5 of 9 running projects, newest first. Listed amounts together: €48.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D

  NCT07845955· Huijie Zhang· Source

• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

  NCT05743244· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 10
• Organoids 4
• Mendelian Randomization Analysis 35
• CRISPR-Cas Systems 5
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 12
• Immunohistochemistry 16
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 33
• Machine Learning 31
• Deep Learning 10
• Cohort Studies 158
• Genome-Wide Association Study 54

• Effects of STZ-Induced Diabetes on Zinc, Boron and Antioxidant Defense Mechanisms in Rats.

  Niger J Clin Pract, Mar 2025

• A novel 3D-printed centrifugal ultrafiltration method reveals in vivo glycation of human serum albumin decreases its binding affinity for zinc.

  Metallomics, Jul 2020

• Zinc and Other Metals Deficiencies and Risk of Type 1 Diabetes: An Ecological Study in the High Risk Sardinia Island.

  PLoS One, Nov 2015

• Antigenic proteins of Lactobacillus acidophilus that are recognised by serum IgG antibodies in children with type 1 diabetes and coeliac disease.

  Pediatr Allergy Immunol, Jul 2009

See which targets of this disease your abstract mentions, and go to the people working on them.